慢性肝病中代谢基因的融合体突变
Stanley W K Ng1, Foad J Rouhani1,2, Simon F Brunner1
1Cancer Genome Project, Wellcome Sanger Institute, Hinxton, UK.
Nature
|October 14, 2021
概括
在慢性肝病,包括与酒精有关的非酒精性脂肪肝病中,经常观察到FOXO1,CIDEB和GPAM等关键代谢基因的体质突变.
科学领域:
- 基因组学
- 肝病学
- 癌症生物学
背景情况:
- 慢性肝病向肝细胞癌的进展涉及癌症基因的体质突变.
- 慢性肝病的体性突变负担和克隆扩张比正常肝脏更高,促进了积极选择.
- 肝病中的基因组格局受积极选择压力影响.
研究的目的:
- 从34个肝脏样本中分析1590个基因组的体质突变,包括健康对照,与酒精有关的肝病 (ARLD) 和非酒精性脂肪性肝病 (NAFLD).
- 研究特定基因,如FOXO1,CIDEB和GPAM在肝病突变中的作用.
- 在肝病背景下识别体质突变的融合进化模式.
主要方法:
- 在健康的ARLD和NAFLD肝脏组织中对1590个样本进行全基因组测序.
- 在34个肝脏样本中分析体质突变,以确定受影响的基因和突变热点.
- 研究与特定基因突变相关的克隆进化和扩张模式.
主要成果:
- 在29名肝病患者中,有7名患有FOXO1突变,FOXO1是关键的胰岛素信号转录因子,影响了单个热点并影响了核输出.
- 在FOXO1突变 (S22W热点) 中观察到融合进化,每位患者多达9个独立的肝细胞克隆.
- 参与脂质新陈代谢的CIDEB和GPAM也表现出多余的突变,频繁的趋同演变 (每名患者多达14个和7个克隆).
- 代谢基因突变在肝脏部分普遍存在,克隆大小增加,在ARLD和NAFLD中发生,但在肝细胞癌中很少见.
结论:
- 在ARLD和NAFLD中,代谢通路的主调节者经常是合体位突变的目标.
- 代谢基因突变的融合演变表明慢性肝病具有强大的选择性压力.
- 这些发现突显了代谢失调和体质突变在慢性肝病的发病过程中的作用.
更多相关视频
相关概念视频
02:21Cancers Originate from Somatic Mutations in a Single Cell
13.2K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.2K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
24
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
24
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
26
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
26
02:53Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
19
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
19
01:19Regulation of Metabolism
10.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
10.4K